Cellular Biomedicine Group Announces New Facility in Beijing

Cellular Biomedicine Group Inc.

("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that the Company, in anticipation of growth in the Beijing vicinity and further development of the CAR-T platform, has signed a new five-year lease for a 15,000 square feet site slated for the Company's third GMP facility which will also expanded staffing in the Life Science Park, Changping District, Beijing, China. Approximately half of the site will be a GMP equipped facility to support clinical batch production and commercial scale manufacturing. We expect to complete the state-of-the-art GMP facility in Q3 this year. "Having already established a world-class biomedicine facility in Shanghai, China, this expansion to Beijing will allow us to prepare for increasing manufacture demand from our immuno-oncology and human adipose-derived mesenchymal progenitor cell (haMPC) platforms in the near future," said William (Wei) Cao, PhD, BM, Chief Executive Officer of Cellular Biomedicine Group. "In addition, housing our vertically integrated research and development and production systems in several locations, particularly Beijing, enables the Company to deliver consistent quality measures across the whole northern China region, thereby better serving the Company's patient population."